Last reviewed · How we verify
TG-2349 as a new capsule formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TG-2349 as a new capsule formulation (TG-2349 as a new capsule formulation) — TaiGen Biotechnology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TG-2349 as a new capsule formulation TARGET | TG-2349 as a new capsule formulation | TaiGen Biotechnology Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TG-2349 as a new capsule formulation CI watch — RSS
- TG-2349 as a new capsule formulation CI watch — Atom
- TG-2349 as a new capsule formulation CI watch — JSON
- TG-2349 as a new capsule formulation alone — RSS
Cite this brief
Drug Landscape (2026). TG-2349 as a new capsule formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/tg-2349-as-a-new-capsule-formulation. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab